

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**KINGWORLD MEDICINES GROUP LIMITED**

**金活醫藥集團有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

(Stock Code : 01110)

## **UNUSUAL PRICE AND TRADING VOLUME MOVEMENTS**

This announcement is made by Kingworld Medicines Group Limited (the “**Company**”) at the request of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) pursuant to Rule 13.10 of the Rules Governing the Listing of Securities on the Stock Exchange.

The board of directors (the “**Board**”) of the Company has noted the increases in the price and trading volume of the shares of the Company on 17 April 2014. Having made such enquiry with respect to the Company as is reasonable in the circumstances, the Board confirms that it is not aware of any reasons for such increases in the price and trading volume or of any information which must be announced to avoid a false market in the Company’s securities or of any inside information that needs to be disclosed under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Board has also noted recent news articles regarding (among other things) the registration of “Pu Ji Kang Gan Granules (普濟抗感顆粒)” as proprietary Chinese medicine by the Department of Health of Hong Kong. The Board confirms that Yuen Tai Pharmaceuticals Limited (遠大製藥廠有限公司) has been issued with a certificate of registration of proprietary Chinese medicine in respect of “Pu Ji Kang Gan Granules” by the Chinese Medicines Board and is allowed to sell the medicine in Hong Kong. The medicine will be distributed by the Company and its subsidiaries pursuant to the Yuen Tai master distribution agreement dated 16 November 2012 entered into between the Company and Yuen Tai Pharmaceuticals Limited.

**Potential investors and/or shareholders of the Company are advised to exercise caution when dealing in the shares of the Company.**

This announcement is made by the order of the Company. The Board collectively and individually accepts responsibility for the accuracy of this announcement.

By order of the Board  
**Kingworld Medicines Group Limited**  
**Zhao Li Sheng**  
*Chairman*

Hong Kong, 17 April 2014

*As at the date of this announcement, the executive Directors are Mr. Zhao Li Sheng, Ms. Chan Lok San, Mr. Zhou Xuhua and Mr. Lin Yusheng, and the independent non-executive Directors are Mr. Duan Jidong, Mr. Zhang Jianbin and Mr. Wong Cheuk Lam.*